Rachael A. Potter

1.2k total citations · 1 hit paper
30 papers, 667 citations indexed

About

Rachael A. Potter is a scholar working on Molecular Biology, Genetics and Surgery. According to data from OpenAlex, Rachael A. Potter has authored 30 papers receiving a total of 667 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 15 papers in Genetics and 7 papers in Surgery. Recurrent topics in Rachael A. Potter's work include Muscle Physiology and Disorders (27 papers), Virus-based gene therapy research (15 papers) and CAR-T cell therapy research (6 papers). Rachael A. Potter is often cited by papers focused on Muscle Physiology and Disorders (27 papers), Virus-based gene therapy research (15 papers) and CAR-T cell therapy research (6 papers). Rachael A. Potter collaborates with scholars based in United States, Switzerland and United Kingdom. Rachael A. Potter's co-authors include Louise R. Rodino‐Klapac, Danielle A. Griffin, Jerry R. Mendell, Kelly J. Lehman, Eric R. Pozsgai, Sarah Lewis, Zarife Sahenk, Lindsay N. Alfano, Linda Lowes and M. Iammarino and has published in prestigious journals such as Nature Medicine, SHILAP Revista de lepidopterología and Neurology.

In The Last Decade

Rachael A. Potter

30 papers receiving 655 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy

2020 264 citations Jerry R. Mendell, Zarife Sahenk et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rachael A. Potter United States	11	581	272	153	129	74	30	667
Eric R. Pozsgai United States	10	567 1.0×	229 0.8×	149 1.0×	136 1.1×	64 0.9×	19	634
Xiomara Q. Rosales United States	10	533 0.9×	189 0.7×	164 1.1×	124 1.0×	90 1.2×	17	653
N. Miller United States	8	447 0.8×	171 0.6×	99 0.6×	189 1.5×	48 0.6×	33	562
Nicolas Wein United States	17	639 1.1×	146 0.5×	126 0.8×	134 1.0×	80 1.1×	34	684
Chun Long United States	9	852 1.5×	400 1.5×	311 2.0×	69 0.5×	155 2.1×	13	947
Takako I. Jones United States	19	909 1.6×	120 0.4×	225 1.5×	242 1.9×	56 0.8×	32	948
Kim Shontz United States	5	374 0.6×	133 0.5×	86 0.6×	80 0.6×	73 1.0×	11	445
Julian N. Ramos United States	9	366 0.6×	167 0.6×	65 0.4×	40 0.3×	58 0.8×	10	401
Natalie Farra Canada	5	405 0.7×	128 0.5×	62 0.4×	37 0.3×	41 0.6×	6	491
James S. Novak United States	14	599 1.0×	69 0.3×	81 0.5×	92 0.7×	154 2.1×	21	678

Countries citing papers authored by Rachael A. Potter

Since Specialization

Citations

This map shows the geographic impact of Rachael A. Potter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachael A. Potter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachael A. Potter more than expected).

Fields of papers citing papers by Rachael A. Potter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachael A. Potter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachael A. Potter. The network helps show where Rachael A. Potter may publish in the future.

Co-authorship network of co-authors of Rachael A. Potter

This figure shows the co-authorship network connecting the top 25 collaborators of Rachael A. Potter. A scholar is included among the top collaborators of Rachael A. Potter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachael A. Potter. Rachael A. Potter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Potter, Rachael A., Sohrab Khan, Hélène Haegel, et al.. (2025). Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy. Scientific Reports. 15(1). 4–4. 8 indexed citations

Rodino‐Klapac, Louise R., et al.. (2024). Long-Term Survival and Myocardial Function Following Systemic Delivery of Delandistrogene Moxeparvovec in DMD ^MDX Rats. Human Gene Therapy. 35(23-24). 978–988. 5 indexed citations

Potter, Rachael A., et al.. (2024). Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74. Molecular Therapy — Methods & Clinical Development. 32(1). 101195–101195. 19 indexed citations

Mendell, Jerry R., Eric R. Pozsgai, Sarah Lewis, et al.. (2024). Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results. Nature Medicine. 30(1). 199–206. 9 indexed citations

Potter, Rachael A., Danielle A. Griffin, Kristin N. Heller, Jerry R. Mendell, & Louise R. Rodino‐Klapac. (2023). Expression and function of four AAV-based constructs for dystrophin restoration in the mdx mouse model of Duchenne muscular dystrophy. Biology Open. 12(9). 1 indexed citations

Mendell, Jerry R., Zarife Sahenk, Kelly J. Lehman, et al.. (2023). Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial. Muscle & Nerve. 69(1). 93–98. 37 indexed citations

Zaidman, Craig M., Crystal M. Proud, Craig M. McDonald, et al.. (2023). Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP‐9001‐103 (ENDEAVOR). Annals of Neurology. 94(5). 955–968. 47 indexed citations

Mendell, Jerry R., Perry B. Shieh, Craig M. McDonald, et al.. (2023). Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Frontiers in Cell and Developmental Biology. 11. 1167762–1167762. 42 indexed citations

Potter, Rachael A., S A Khan, Jenna Snedeker, et al.. (2023). P17 Safety and efficacy of pre-treatment with imlifidase prior to AAV-based gene therapy in non-human primates with pre-existing anti-AAVrh74 antibodies. Neuromuscular Disorders. 33. S101–S101. 1 indexed citations

10.

Lewis, Sarah, et al.. (2023). Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model. Molecular Therapy — Methods & Clinical Development. 28. 284–299. 10 indexed citations

11.

Mendell, Jerry R., Perry B. Shieh, Zarife Sahenk, et al.. (2023). A Phase 2 Clinical Trial Evaluating the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Patients with Duchenne Muscular Dystrophy (DMD) (S48.004). Neurology. 100(17_supplement_2). 4 indexed citations

12.

Sahenk, Zarife, Kelly J. Lehman, Linda Lowes, et al.. (2023). Long-term Safety and Efficacy in Patients with DMD 4 Years Post-Treatment with Delandistrogene Moxeparvovec (SRP-9001) in a Phase 1/2a Study (P3-8.006). Neurology. 100(17_supplement_2). 2 indexed citations

13.

O’Rourke, Erin, Jerry R. Mendell, Zarife Sahenk, et al.. (2023). P314: Long-term safety and sustained functional benefit in patients with DMD 4 years post-treatment with delandistrogene moxeparvovec: A phase 1/2a study*. SHILAP Revista de lepidopterología. 1(1). 100342–100342. 1 indexed citations

14.

Mendell, Jerry R., Zarife Sahenk, Kelly J. Lehman, et al.. (2022). Phase 1/2a Trial of SRP-9001 in Patients with Duchenne Muscular Dystrophy: 3-Year Safety and Functional Outcomes (S23.004). Neurology. 98(18_supplement). 1 indexed citations

15.

Potter, Rachael A., et al.. (2021). Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy. Human Gene Therapy. 32(7-8). 375–389. 51 indexed citations

16.

Mendell, Jerry R., Perry B. Shieh, Zarife Sahenk, et al.. (2021). A Multicenter Randomized, Double-Blind, Placebo-Controlled, Gene-Delivery Clinical Trial of rAAVrh74.MHCK7.micro-dystrophin for Duchenne Muscular Dystrophy (4478). Neurology. 96(15_supplement). 2 indexed citations

17.

Griffin, Danielle A., et al.. (2020). Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular Dystrophy. Human Gene Therapy. 32(7-8). 390–404. 16 indexed citations

18.

Asher, Damon R., et al.. (2020). Clinical development on the frontier: gene therapy for duchenne muscular dystrophy. Expert Opinion on Biological Therapy. 20(3). 263–274. 59 indexed citations

19.

Potter, Rachael A., Danielle A. Griffin, R.W. Johnson, et al.. (2017). Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy. Human Gene Therapy. 29(7). 749–762. 41 indexed citations

20.

Marino, Joseph, Terry D. Hinds, Rachael A. Potter, et al.. (2013). Suppression of protein kinase C theta contributes to enhanced myogenesis In vitro via IRS1 and ERK1/2 phosphorylation. BMC Cell Biology. 14(1). 39–39. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact